US embassy attacks Dutch govt plans to "undermine" IP
The US embassy in the Netherlands has expressed its concern about the Dutch government’s plans to “undermine” IP rights for medicines.
Canadian cannabis brand blocked from UK TM registration
The UK Intellectual Property Office has blocked Canadian brand Vivo Cannabis from registering ‘Lumina’ as a trademark, after an opposition from an Italian pharmaceutical company.
Biogen fights off Mylan’s Tecfidera patent challenge
US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
Mewburn Ellis hires in Munich
European patent attorney Dr. Thomas Wolter has joined the Munich office of European IP law firm Mewburn Ellis.
Gilead suffers defeat at PTAB in government PrEP battle
Gilead has suffered a blow in its efforts to invalidate the US government’s patent rights for PrEP, as the Patent Trial and Appeal Board threw out two of its four patent challenges.
Chinese institute tries to patent Gilead coronavirus drug
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.
BMS partners with drug accelerator to launch biotech
Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Antitrust regulators to increase scrutiny of biosimilar deals
US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Idenix $2.5bn ruling will impede innovation, says Amgen
Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
CIPA and UKIPO join forces to change misleading Brexit advice
The UK Intellectual Property Office and the Chartered Institute of Patent Attorneys have worked together to ensure changes are made to “misleading” advice issued by the EU’s Community Plant Variety Office.
